Neurodevelopmental Outcomes After Bevacizumab Treatment for Retinopathy of Prematurity-A Meta-Analysis.

Please login or register to bookmark this article
Bookmark this %label%

To evaluate neurodevelopmental outcomes after intravitreal bevacizumab (IVB) in retinopathy of prematurity (ROP) infants compared to those not exposed to IVB.The primary concern regarding IVB treatment of ROP is the potential systemic side effects, especially the risk of causing severe neurodevelopmental impairment (sNDI). Results regarding neurodevelopmental outcomes after IVB are conflicting.We conducted a meta-analyses and searched PubMed, Embase, and Web of Science for related publications from inception to March 12, 2020. The eligibility criteria were as follows: comparative studies of ROP patients that (1) included IVB as a treatment arm; (2) included a control group without bevacizumab treatment; and (3) reported on at least one neurodevelopmental outcome, such as sNDI, Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) composition scores, or cerebral palsy (CP). The Newcastle-Ottawa Scale was employed for risk-of-bias assessment. The primary outcome was sNDI, with the odds ratio (OR) calculated. Secondary outcomes were mean differences (MDs) for cognitive, language, and motor scores (Bayley-III) and OR for CP. The quality of evidence was assessed using the GRADE approach.Eight studies, namely 6 including laser-controlled ROP infants and 2 including ROP infants not requiring treatment, were included. The weighted OR for sNDI in the IVB group was 1.39 (95% confidence interval [CI]: 0.98 to 1.97). The weighted MDs were -2.10 (95% CI: -4.94 to 0.74), -1.32 (95% CI: -4.65 to 1.99), and -3.66 (95% CI: -6.79 to -0.54) for cognitive, language, and motor scores in Bayley-III, respectively. The OR for CP was 1.20 (95% CI: 0.56 to 2.55). No differences were observed between the preset subgroups comprising laser-controlled ROP infants and ROP infants not requiring treatment. The current quality of evidence was rated as low (sNDI and all Bayley-III scores) to very low (CP).sNDI risk was not increased in ROP patients after IVB treatment. Bayley-III scores were similar in the IVB and control groups, except for a minor difference in motor performance. These findings suggest that the risk of additional sNDI after IVB treatment is low. Randomized trials are warranted to provide a higher quality of evidence.

View the full article @ Ophthalmology
Get PDF with LibKey